Phase II trial alone may not support BLA for Voyager's Parkinson's gene therapy

Voyager Therapeutics Inc. (NASDAQ:VYGR) said late Wednesday that FDA now considers a randomized Phase II trial of VY-AADC to be an "early phase exploratory study,"

Read the full 250 word article

User Sign In